key: cord-0779108-hn9gea50
authors: Rossetti, Arianna; Gheihman, Galina; O'Hare, Meabh; Kosowsky, Joshua M.
title: Guillain-Barré Syndrome presenting as facial diplegia after COVID-19 vaccination: a case report
date: 2021-08-07
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2021.07.062
sha: 701b3f85641f88aa532fcda8b5f3f46da20d159c
doc_id: 779108
cord_uid: hn9gea50

BACKGROUND: Guillain-Barré Syndrome (GBS) is a rapidly progressive immune-mediated polyneuropathy often associated with an antecedent infectious illness or vaccination. The classic presentation of GBS is characterized by ascending limb weakness and numbness with loss of reflexes. However, atypical variants involving the face and arms or with purely sensory symptoms also exist. In up to 30 percent of cases, GBS progresses to respiratory failure, with patients requiring mechanical ventilation. CASE REPORT: We report a case of atypical GBS occurring after COVID-19 vaccination in an otherwise healthy 38-year-old male. The patient's clinical presentation was characterized by bilateral hand and foot paresthesias, dysarthria, bilateral facial weakness, and an absence of classic ascending limb weakness. Albuminocytological dissociation within the cerebrospinal fluid was suggestive of GBS. The patient received intravenous immunoglobulin (IVIG) therapy with modest improvement in his symptoms at the time of the patient's discharge from the hospital. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS? Patients with GBS are at risk for life threatening complications including respiratory failure requiring mechanical ventilation. It is critical for Emergency physicians to be aware of the manifold presentations of GBS for early recognition and treatment. This may be of particular importance in the context of a worldwide vaccination campaign in response to the COVID-19 pandemic.

Guillain-Barré Syndrome (GBS) is a rapidly progressive immune-mediated polyneuropathy often associated with an antecedent infectious illness or vaccination. Classically the syndrome is characterized by symmetric paresthesias, weakness of the extremities, or diminished or absent reflexes. Atypical variants involving the face and arms or with purely sensory symptoms have also been identified. 1 In up to 30 percent of cases, 2 GBS progresses to respiratory failure, with patients requiring mechanical ventilation. Therefore, it is critical for Emergency physicians to rapidly recognize the signs and symptoms of this disorder for timely diagnosis and initiation of treatment. Most patients will require admission for expedited workup, initiation of immunemodulatory therapy, and monitoring for respiratory compromise. We report a case of an atypical presentation of GBS presenting with extremity paresthesias, dysarthria, and bilateral facial weakness, in the absence of classic ascending limb weakness, and discuss differential diagnosis, triage, and management.

A 38-year-old male presented to the Emergency Department (ED) with facial weakness, slurred speech, and bilateral hand and foot paresthesias. The patient had been in a state of good health upon receipt of the Johnson & Johnson COVID-19 vaccine 32 days prior. Approximately 2 weeks after vaccination, the patient developed numbness and tingling in his tongue, lips, and bilateral hands and feet. Two days prior to presentation the patient began to develop difficulty moving his mouth and forming words, as well as difficulty drinking from a straw and controlling his lips, cheeks, and tongue while eating. Review of systems was notable for headaches, mild gait unsteadiness, generalized fatigue, and dyspnea on exertion. The patient denied diplopia, dysphagia, or dysphonia; chest pain or palpitations; lightheadedness; fevers or chills; nausea, vomiting, or diarrhea; urinary or bowel incontinence; and falls or other trauma. Past medical history was notable for anxiety and depression for which the patient takes Bupropion. The patient reported drinking on average 6-8 beers per day and using marijuana daily.

The patient presented in clinically good condition, not in acute distress and ambulating independently. Initial vital signs were as follows; blood pressure 218/80 mmHg, heart rate 85/min, respiratory rate 16/min and oxygen saturation of 100%. The physical examination was notable for significant dysarthria and bilateral facial weakness in a lower-motor-neuron-pattern.

The patient exhibited weak eye closure bilaterally and inability to smile or puff cheeks against resistance. Extra-ocular movements were intact, and tongue was midline without fasciculations.

Strength in the upper and lower extremities was intact (5/5) as was sensation to light touch throughout. There was no dysmetria or gait ataxia. Deep tendon reflexes were reduced, 1+ in the lower extremities and only faintly present in the bilateral upper extremities.

Laboratory studies were notable for a white blood cell count of 12.25 x10 3 /mL with a normal differential, a hemoglobin of 16.7 g/dl and a hematocrit of 49.5 L/L. Serum chemistries including tests of liver function, TSH, folate, and B12, were all within normal limits. Urine toxicology was positive for THC, and COVID-19 PCR was negative. The patient was admitted and received intravenous immunoglobulin (IVIG) over two days to a total dose of 2g/kg with mild improvement of his symptoms. Measurements of negative inspiratory force (NIF) were performed daily, and the patient did not develop any signs or symptoms of respiratory compromise. On hospital day 1, the patient developed new hyponatremia which reached a nadir of 124 during admission. This was concluded to be multifactorial, attributed to pseudohyponatremia in the setting of IVIG as well as SIADH in the setting of GBS. The patient was treated with fluid restriction and salt tabs with improvement in sodium to 134 on discharge. The patient's symptoms showed no further progression and he was discharged home on hospital day 4. The discharge examination was notable for stable to improving bilateral facial weakness and dysarthria with generalized areflexia.

We describe the case of a 38-year-old male who developed subacute, rapidly progressive, bilateral hand and foot paresthesias, dysarthria, and bilateral facial weakness in the setting of recent COVID-19 vaccination. This was thought to represent an atypical variant of GBS with absence of classic ascending limb weakness but presence of diminished reflexes on examination. Facial weakness is present as an associated symptom in as many as 70 percent of cases of GBS and is usually bilateral. 2,3 Atypical variants of GBS differ in presentation and severity and include pure sensory, pure motor, or autonomic variants. 2 The Miller-Fisher variant includes ophthalmoplegia, ataxia, and areflexia with minimal weakness. The pharyngealcervical-brachial variant causes dysphagia, neck plegia, and proximal arm weakness. Our patient presented with the facial diplegia with acral paresthesias variant, which is characterized by isolated bilateral facial weakness and minimal if any extremity weakness. 4, 5 Bilateral facial nerve palsy is an uncommon presentation with a limited differential diagnosis, including GBS, Lyme disease, Varicella-Zoster virus (VZV), acute human immunodeficiency virus (HIV) infection, or neurosarcoidosis. 6 Inflammatory or infiltrative disease involving the leptomeninges at the level of the brainstem (e.g. leptomeningeal carcinomatosis or tuberculous meningitis) can also present with facial diplegia, although more often in association with additional cranial neuropathies. A vascular etiology (e.g. pontine stroke involving bilateral cranial nerve (CN) VII nuclei or fascicles) is very unlikely to cause isolated bilateral facial paralysis without other brainstem symptoms and signs. 7 Toxic or metabolic derangements including excessive alcohol use, as well as vitamin deficiencies are on the differential for peripheral neuropathy but are also very unlikely to present as isolated bilateral facial weakness.

In each of the infectious or inflammatory conditions on the differential above, CN-VII enhancement may be seen on MRI of the brain. 8 The most feared complication of GBS is respiratory failure. 11 Respiratory evaluation is of the highest importance when determining disposition in the Emergency Department, as patients who may require intubation or mechanical ventilation should be triaged to the ICU. 12 Risk factors for mechanical ventilation include presence of facial nerve palsy, short interval from onset of symptoms to admission, and glossopharyngeal or vagal nerve deficits (i.e. poor cough and gag reflexes). 13 Although pulse oximetry may be normal at initial presentation, it is insufficient to rule out respiratory compromise as respiratory weakness may lead to hypercarbia without significant hypoxia. Instead, patients should be evaluated by measuring lung mechanics and negative inspiratory force (NIF), which can be serially monitored. Additional complications include hyponatremia, which our patient developed, as well as autonomic dysfunction.

Hyponatremia is associated with GBS and is thought to be secondary to the syndrome of inappropriate anti-diuretic hormone (SIADH); it correlates with the severity of GBS and is an indicator of poor prognosis. 14 In the case of facial weakness, corneal inflammation from inability to close the eye(s) may be an additional complication.

Initial management of GBS includes rapid initiation of IVIG or plasmapheresis, which appear to be equivalent in efficacy and hasten the time to recovery. 15 Treatment should be in the inpatient setting with frequent monitoring as progression of disease may require intensive care. 11, 12 Most symptoms peak within 4-8 weeks. Weakness and paresthesias typically begin to recover after about one month, but it may take several months for patients to return to their pre-morbid baseline. Some patients will continue to experience sensorimotor deficits long term 2 and may benefit from physical, occupational, and speech language pathology therapy. 16 GBS is classically preceded by an acute diarrheal or respiratory illness in the weeks prior to presentation, but has also been associated with recent vaccination. 17 To date, there has been a small but statistically significant association found between influenza vaccination and GBS. 18 The risk of GBS is estimated to be in the range of 1-2 additional GBS cases per 1 million influenza vaccine doses administered. 18 Concerns have been raised linking GBS with the measles/mumps/rubella, human papillomavirus, and quadrivalent conjugated meningococcal vaccines; however the association between vaccine administration and an increased incidence above chance of GBS has only been proven with the influenza vaccine. 19 In this case report, the patient received the 

Atypical guillain-barré in the emergency department

Guillain-Barré syndrome and variants

Assessment of current diagnostic criteria for Guillain-Barré syndrome

Facial Diplegia with Paresthesia: An Uncommon Variant of Guillain-Barre Syndrome

A Guillain-Barré syndrome variant with prominent facial diplegia

Isolated facial diplegia in Guillain-Barré syndrome: Bifacial weakness with paresthesias. Muscle Nerve

When is facial diplegia regarded as a variant of Guillain-Barré syndrome?

Cranial Nerve Enhancement in Guillain-Barré Syndrome

MRI 3D CISS-A Novel Imaging Modality in Diagnosing Trigeminal Neuralgia -A Review

Imaging of cranial nerves: a pictorial overview

Complications of Guillain-Barré syndrome

Intensive Care and Treatment of Severe Guillain-Barré Syndrome

Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome

Guillain-Barré syndrome and SIADH

Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev

Chronic inflammatory demyelinating polyneuropathy

Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence

The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses

Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. Vaccine

Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: Temporal associations do not imply causality

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine

Quelling public fears about Guillain-Barré syndrome and COVID-19 vaccination

Vaccines for COVID-19

World Health Organization. COVID-19 advice for the public: Getting vaccinated